Evidence map›Paper›PMID 36233006›Full record

ArticleInternational journal of molecular sciences2022

Resvega, a Nutraceutical Preparation, Affects NFκB Pathway and Prolongs the Anti-VEGF Effect of Bevacizumab in Undifferentiated ARPE-19 Retina Cells.

Randa Sghaier, Maude Perus, Clarisse Cornebise, Flavie Courtaut, Alessandra Scagliarini, Céline Olmiere, Virginie Aires, François Hermetet, Dominique Delmas

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. International journal of ophthalmology · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Randa SghaierUFR des Sciences de Santé, Université de Bourgogne, 21000 Dijon, France.ORCID 0000-0001-9314-1598
Maude PerusUFR des Sciences de Santé, Université de Bourgogne, 21000 Dijon, France.
Clarisse CornebiseUFR des Sciences de Santé, Université de Bourgogne, 21000 Dijon, France.ORCID 0000-0003-0038-3809
Flavie CourtautUFR des Sciences de Santé, Université de Bourgogne, 21000 Dijon, France.
Alessandra ScagliariniUFR des Sciences de Santé, Université de Bourgogne, 21000 Dijon, France.
Céline OlmiereLaboratoires Théa®, 12 Rue Louis-Blériot, 63000 Clermont-Ferrand, France.ORCID 0000-0001-7551-1129
Virginie AiresUFR des Sciences de Santé, Université de Bourgogne, 21000 Dijon, France.
François HermetetUFR des Sciences de Santé, Université de Bourgogne, 21000 Dijon, France.ORCID 0000-0001-5549-1992
Dominique DelmasUFR des Sciences de Santé, Université de Bourgogne, 21000 Dijon, France.
Inserm · FRThea (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Age-related macular degeneration (AMD) is an irreversible chronic degenerative pathology that affects the retina. Despite therapeutic advances thanks to the use of anti-vascular endothelial growth factor (VEGF) agents, resistance mechanisms have been found to accentuate the visual deficit. In the present study, we explored whether a nutraceutical formulation composed of omega-3 fatty acids and resveratrol, called Resvega

Indexed as

Fatty Acids, Omega-3Macular DegenerationBevacizumabDietary SupplementsEndothelial Growth FactorsHumansI-kappa B KinaseNF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktResveratrolRetinaTOR Serine-Threonine KinasesVascular Endothelial Growth Factor ABevacizumabEndothelial Growth FactorsFatty Acids, Omega-3I-kappa B KinaseNF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktResveratrolTOR Serine-Threonine KinasesVascular Endothelial Growth Factor AAMDangiogenesisanti-VEGFocular diseasesomega-3 fatty acidsResvegaresveratrol

Identifiers

PMID36233006
PMCPMC9569823
OpenAlexW4303699621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.